These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37672016)

  • 61. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.
    Kane JM; Osuntokun O; Kryzhanovskaya LA; Xu W; Stauffer VL; Watson SB; Breier A
    J Clin Psychiatry; 2009 Apr; 70(4):572-81. PubMed ID: 19323965
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan.
    Iwata N; Inagaki A; Sano H; Niidome K; Kojima Y; Yamada S
    Adv Ther; 2020 Jul; 37(7):3324-3336. PubMed ID: 32500455
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia.
    Peuskens J; Bervoets C; Kok F; Delatte B; Touquet G; Gillain B; de Patoul A; Halkin V; Loze JY; Vansteelandt K; Constant E
    Eur Psychiatry; 2012 Oct; 27(7):506-12. PubMed ID: 21920707
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies.
    Schöttle D; Clerzius G; Janetzky W; Oluboka O; Roy MA; Therrien F; Wiedemann K
    Eur Psychiatry; 2022 Jul; 65(1):e42. PubMed ID: 35855645
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan.
    Matsumoto H; Ishigooka J; Ono H; Tadori Y
    Psychiatry Clin Neurosci; 2018 Sep; 72(9):701-712. PubMed ID: 29774635
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
    San L; Estrada G; Oudovenko N; Montañés F; Dobrovolskaya N; Bukhanovskaya O; Popov M; Vieta E
    Eur Neuropsychopharmacol; 2018 Jun; 28(6):710-718. PubMed ID: 29724638
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
    J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
    Weiden PJ; Du Y; Liu CC; Stanford AD
    CNS Spectr; 2019 Aug; 24(4):419-425. PubMed ID: 29941057
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data.
    Waters HC; Stellhorn R; Touya M; Fitzgerald H; Bhattacharjee S; Citrome L
    J Med Econ; 2023; 26(1):316-325. PubMed ID: 36780296
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
    Pigott TA; Carson WH; Saha AR; Torbeyns AF; Stock EG; Ingenito GG;
    J Clin Psychiatry; 2003 Sep; 64(9):1048-56. PubMed ID: 14628980
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
    Risinger R; Hard M; Weiden PJ
    Psychopharmacol Bull; 2017 Aug; 47(3):26-34. PubMed ID: 28839337
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-Term Improvement and Safety of Aripiprazole for Irritability and Adaptive Function in Asian Children and Adolescents with Autistic Disorder: A 52-Week, Multinational, Multicenter, Open-Label Study.
    Kim BU; Kim HW; Park EJ; Kim JH; Boon-Yasidhi V; Tarugsa J; Reyes A; Manalo SG; Joung YS
    J Child Adolesc Psychopharmacol; 2022 Sep; 32(7):390-399. PubMed ID: 36112116
    [No Abstract]   [Full Text] [Related]  

  • 74. Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia.
    Najarian D; Turkoz I; Knight RK; Galderisi S; Lamaison HF; Zalitacz P; Aravind S; Richarz U
    Int J Neuropsychopharmacol; 2023 Aug; 26(8):537-544. PubMed ID: 37480362
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.
    Bervoets C; Morrens M; Vansteelandt K; Kok F; de Patoul A; Halkin V; Pitsi D; Constant E; Peuskens J; Sabbe B
    CNS Drugs; 2012 Nov; 26(11):975-82. PubMed ID: 23018547
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
    Barber S; Olotu U; Corsi M; Cipriani A
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006324. PubMed ID: 28333365
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index.
    Schöttle D; Janetzky W; Luedecke D; Beck E; Correll CU; Wiedemann K
    BMC Psychiatry; 2020 Feb; 20(1):77. PubMed ID: 32087718
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.
    Correll CU; Kohegyi E; Zhao C; Baker RA; McQuade R; Salzman PM; Sanchez R; Nyilas M; Carson W
    J Am Acad Child Adolesc Psychiatry; 2017 Sep; 56(9):784-792. PubMed ID: 28838583
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392).
    Carlson BX; Ketter TA; Sun W; Timko K; McQuade RD; Sanchez R; Vester-Blokland E; Marcus R
    Bipolar Disord; 2012 Feb; 14(1):41-53. PubMed ID: 22329471
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder.
    Cantillon M; Prakash A; Alexander A; Ings R; Sweitzer D; Bhat L
    Schizophr Res; 2017 Nov; 189():126-133. PubMed ID: 28215471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.